Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.37, $0.28 better than the analyst estimate of $1.09. Revenue for the quarter came in at $552.97 million versus the consensus estimate of $568.18 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.